SEC Tracker
Get the app

Dermata Therapeutics DRMA

Dermata Therapeutics enrolls first patient in acne trial

Item 8.01 Other events

Form
8-K
Filed
Importance
Routine
  1. First participant enrolled in clinical trial for Tome Clearing Treatment
  2. Company expects to launch second commercial product in H1 2027
  3. Forward-looking statements include product launch timing and market expectations

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Dermata Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Oragenics OGEN public float $3M, Jun 30, 2025
  2. Inhibitor Therapeutics INTI public float $3M, Jun 30, 2025
  3. PTC Therapeutics PTCT public float $3M, Jun 30, 2025
  4. Integrated Biopharma INBP public float $3M, Dec 31, 2025
  5. Enveric Biosciences ENVB public float $4M, Jun 30, 2025